Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED)
Authors not listed
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 2008
Abstract
Patients with Pigment Epithelial Detachments secondary to Age-Related Macular Degeneration (AMD) will receive intravitreal Lucentis monthly for 6 months in the hope of improving visual acuity from a baseline evaluation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2008). Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED). <em>London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's</em>. https://clinicaltrials.gov/study/NCT00841581
Vancouver
Anonymous. Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED). London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. 2008.
BibTeX
@misc{anon2008Intrav,
title = {Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED)},
author = {Anonymous},
journal = {London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's},
year = {2008},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
IRCCS San Raffaele 2011
Open access · US-GOV
Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration
Retina 2006
Citation only
INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Novartis 2007
Open access · US-GOV
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months
Instituto de Olhos de Goiania 2009
Open access · US-GOV
Comparative Study - Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
Anne Fung MD 2010
Open access · US-GOV
High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study
Clinical Interventions in Aging 2006
Open access · OA